Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Mirum | Rare Historical Photos

Mirum Plans 2027 Hepatitis D Filing After Phase 3 Win as U.S. Patients Rely on One Approved Drug

Mirum's hepatitis D antibody met its Phase 3 goal, and a 2027 FDA filing is planned. Hepcludex remains the only approved U.S. treatment.

Medical Daily · Sep 30

Atebrioz Becomes Third FDA-Approved Drug for Rare FOP, Offering a Daily Pill for Patients 12 and Older

The FDA approved Atebrioz, a daily pill for FOP in patients 12 and older. Here is what the trial showed, the fetal risk, and what it did not measure.

Medical Daily · Sep 28

Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio. Speaking at RBC Capital Markets’ 20

MarketBeat · May 27

From analysis to the latest developments in health,
read the most diverse news in one place.

Mirum Pharma: A Rare Disease Growth Story to Watch

Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company

MarketBeat · May 20

Mirum Pharma Acquires Its Licensing Partner In Cash and Stock

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) has acquired Satiogen Pharmaceuticals Inc in a cash and stock deal. The deal consideration includes 841,792 shares, 199,993 of which are subject to the achievement of a milestone, and approximately $2.8 million in cash. Mirum will wholly own the Satiogen subsidiary, which will receive a 2% royalty. Satiogen was an…

Benzinga · May 23, 2022

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Intellectual Property

392 stories

Read news from The Economist, FT, and more,
with one subscription

Places

United States

422,512 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.